Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates | Synapse
April 1, 2024Open Access
Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Supplementary Figure 1. Change in sum of longest tumor diameters across response assessments in liposarcoma and UPS/Other cohorts.